534 results on '"Casulo, Carla"'
Search Results
2. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
3. Defining primary refractory large B-cell lymphoma
4. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
5. How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
6. Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma
7. Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population
8. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
9. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study
10. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
11. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study
12. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
13. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
14. Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies
15. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
16. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma.
17. Classification of Lymphomas
18. How do you define treatment success in MZL?
19. Early Progressing Follicular Lymphoma
20. How I treat early-relapsing follicular lymphoma
21. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
22. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma
23. POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
24. ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
25. Burkitt lymphoma- a rare but challenging lymphoma
26. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
27. Risk stratification in follicular lymphoma
28. P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
29. Author gender representation of journal reviews and editorials on lymphoma (2017–22)
30. Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database
31. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States
32. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era
33. Transformation of marginal zone lymphoma (and association with other lymphomas)
34. Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
35. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
36. Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
37. Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse
38. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
39. Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma
40. Classification of Lymphomas
41. Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
42. 3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
43. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
44. Transformed follicular non-Hodgkin lymphoma
45. The Role of Hematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphomas
46. FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
47. Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
48. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
49. Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
50. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.